{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:18:37Z","timestamp":1782573517972,"version":"3.54.5"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["EY026664"],"award-info":[{"award-number":["EY026664"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pennsylvania Lions Sight Conservation and Eye Research Foundation Grant"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0225643","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T18:48:37Z","timestamp":1575312517000},"page":"e0225643","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-0528","authenticated-orcid":true,"given":"Qing-Qing","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-2349","authenticated-orcid":true,"given":"Jingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"issue":"5","key":"pone.0225643.ref001","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(01)01015-6","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome","volume":"109","author":"BP Connolly","year":"2002","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0225643.ref002","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age","volume":"115","author":"GE Quinn","year":"2008","journal-title":"Ophthalmology"},{"issue":"7","key":"pone.0225643.ref003","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0161-6420(98)97036-1","article-title":"Prevalence of myopia between 3 months and 5 1\/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"105","author":"GE Quinn","year":"1998","journal-title":"Ophthalmology"},{"issue":"12","key":"pone.0225643.ref004","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1167\/iovs.10-5234","article-title":"Long-term evaluation of refractive status and optical components in eyes of children born prematurely","volume":"51","author":"TC Chen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"pone.0225643.ref005","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1167\/iovs.13-11765","article-title":"Development of refractive error in individual children with regressed retinopathy of prematurity","volume":"54","author":"J Wang","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"pone.0225643.ref006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajo.2006.03.036","article-title":"Intravitreal avastin: the low cost alternative to lucentis?","volume":"142","author":"PJ Rosenfeld","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"pone.0225643.ref007","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"MM Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"pone.0225643.ref008","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"BC Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0225643.ref009","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archophthalmol.2012.1","article-title":"Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"BC Harder","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"pone.0225643.ref010","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis","volume":"122","author":"CK Hwang","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0225643.ref011","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"M Isaac","year":"2015","journal-title":"J AAPOS"},{"issue":"9","key":"pone.0225643.ref012","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"YH Chen","year":"2014","journal-title":"Eye (Lond)"},{"issue":"4","key":"pone.0225643.ref013","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab","volume":"35","author":"SN Chen","year":"2015","journal-title":"Retina"},{"issue":"4","key":"pone.0225643.ref014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000439182","article-title":"Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy","volume":"234","author":"HK Kuo","year":"2015","journal-title":"Ophthalmologica"},{"issue":"1","key":"pone.0225643.ref015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan","volume":"155","author":"WC Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0225643.ref016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"MA Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"issue":"1","key":"pone.0225643.ref017","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after Laser Versus Combined Laser and Bevacizumab Treatment for Type 1 Retinopathy of Prematurity in Zone I","volume":"37","author":"JM Yoon","year":"2017","journal-title":"Retina"},{"issue":"1","key":"pone.0225643.ref018","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jaapos.2012.12.017","article-title":"BEAT-ROP refraction data at age 2 years","volume":"17","author":"M Geloneck","year":"2013","journal-title":"Journal of AAPOS"},{"issue":"6","key":"pone.0225643.ref019","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"B Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"issue":"7","key":"pone.0225643.ref020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":"Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity","volume":"31","author":"R Axer-Siegel","year":"2011","journal-title":"Retina"},{"key":"pone.0225643.ref021","first-page":"4565216","article-title":"Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age","volume":"2018","author":"YC Chen","year":"2018","journal-title":"J Ophthalmol"},{"issue":"5","key":"pone.0225643.ref022","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"M Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"issue":"3","key":"pone.0225643.ref023","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey","volume":"42","author":"M Gunay","year":"2017","journal-title":"Curr Eye Res"},{"issue":"7","key":"pone.0225643.ref024","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children","volume":"42","author":"EU Kabatas","year":"2017","journal-title":"Curr Eye Res"},{"issue":"2","key":"pone.0225643.ref025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000489023","article-title":"Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1","volume":"240","author":"S Kimyon","year":"2018","journal-title":"Ophthalmologica"},{"key":"pone.0225643.ref026","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/OPTH.S110717","article-title":"Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity","volume":"10","author":"CJ Lin","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"pone.0225643.ref027","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity","volume":"2","author":"R Roohipoor","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"pone.0225643.ref028","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09273972.2014.904896","article-title":"Comparing the SureSight autorefractor and the plusoptiX photoscreener for pediatric vision screening","volume":"22","author":"D Silbert","year":"2014","journal-title":"Strabismus"},{"issue":"5","key":"pone.0225643.ref029","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaapos.2009.08.013","article-title":"Accuracy of the Welch Allyn SureSight for measurement of magnitude of astigmatism in 3- to 7-year-old children","volume":"13","author":"EM Harvey","year":"2009","journal-title":"J AAPOS"},{"issue":"3","key":"pone.0225643.ref030","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1167\/iovs.13-13433","article-title":"Accuracy of noncycloplegic retinoscopy, retinomax autorefractor, and SureSight vision screener for detecting significant refractive errors","volume":"55","author":"MT Kulp","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"pone.0225643.ref031","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"HA Mintz-Hittner","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"2","key":"pone.0225643.ref032","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaapos.2012.10.025","article-title":"Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age","volume":"17","author":"GE Quinn","year":"2013","journal-title":"J AAPOS"},{"issue":"6","key":"pone.0225643.ref033","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity","volume":"10","author":"L Pertl","year":"2015","journal-title":"PLoS One"},{"key":"pone.0225643.ref034","article-title":"Long-Term Safety and Efficacy of Intravitreal Bevacizumab (IVB) for Aggressive Posterior Retinopathy of Prematurity (AP-ROP)","author":"P Malhotra","year":"2014","journal-title":"Invest Ophthalmol Vis Sci Annual Meeting Abstract"},{"issue":"1","key":"pone.0225643.ref035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Z Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"pone.0225643.ref036","first-page":"135","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"HA Mintz-Hittner","year":"2016","journal-title":"Eye Brain"},{"key":"pone.0225643.ref037","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"MJ Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"pone.0225643.ref038","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaapos.2016.09.013","article-title":"Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review","volume":"20","author":"K Abri Aghdam","year":"2016","journal-title":"J AAPOS"},{"issue":"7","key":"pone.0225643.ref039","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0225643.ref040","first-page":"189","article-title":"American Academy of Pediatrics Section on O, American Academy of O, American Association for Pediatric O, Strabismus, American Association of Certified O. Screening examination of premature infants for retinopathy of prematurity","volume":"131","author":"WM Fierson","year":"2013","journal-title":"Pediatrics"},{"issue":"12","key":"pone.0225643.ref041","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"pone.0225643.ref042","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2011"},{"issue":"9","key":"pone.0225643.ref043","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"A Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"pone.0225643.ref044","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"MM Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"pone.0225643.ref045","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: A 5 year follow up","volume":"109","author":"N O'Keeffe","year":"2016","journal-title":"Ir Med J"},{"key":"pone.0225643.ref046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment","volume":"192","author":"YS Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"pone.0225643.ref047","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3341\/kjo.2019.0011","article-title":"Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity","volume":"33","author":"HG Kang","year":"2019","journal-title":"Korean J Ophthalmol"},{"issue":"11","key":"pone.0225643.ref048","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/archopht.119.11.1625","article-title":"Cycloplegic refractions in healthy children aged 1 through 48 months","volume":"119","author":"DL Mayer","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"pone.0225643.ref049","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3928\/01913913-20120731-03","article-title":"Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab","volume":"49","author":"CC Tseng","year":"2012","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"6","key":"pone.0225643.ref050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3928\/01913913-20160727-01","article-title":"Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity","volume":"53","author":"P Larranaga-Fragoso","year":"2016","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"2","key":"pone.0225643.ref051","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"BA Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"6","key":"pone.0225643.ref052","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"BC Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"pone.0225643.ref053","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments","volume":"125","author":"DK Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0225643.ref054","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study","volume":"135","author":"DK Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"pone.0225643.ref055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12886-015-0001-7","article-title":"Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease","volume":"15","author":"MN Menke","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"pone.0225643.ref056","first-page":"2027","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity","volume":"9","author":"O Arambulo","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"pone.0225643.ref057","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"MA Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"pone.0225643.ref058","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"AG Salman","year":"2015","journal-title":"Ophthalmic Res"},{"issue":"1","key":"pone.0225643.ref059","doi-asserted-by":"crossref","first-page":"10732","DOI":"10.1038\/s41598-018-28987-6","article-title":"A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity","volume":"8","author":"Y Cheng","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0225643.ref060","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-Term Outcomes after Intravitreal Injections of Conbercept Versus Ranibizumab for the Treatment of Retinopathy of Prematurity","volume":"38","author":"E Jin","year":"2018","journal-title":"Retina"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T12:00:23Z","timestamp":1665144023000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225643"}},"subtitle":[],"editor":[{"given":"Der-Chong","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0225643","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]}}}